At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharma Europe; Chugai Pharmaceutical
- Class Antirheumatics
- Mechanism of Action Immunosuppressants; Tetrahydrofolate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 19 Sep 2006 Discontinued - Phase-I for Rheumatoid arthritis in United Kingdom (PO)
- 19 Sep 2006 Discontinued - Preclinical for Rheumatoid arthritis in Japan (unspecified route)
- 01 Nov 2002 Chugai Pharmaceutical has been acquired by Roche